Expert Review of Anticancer Therapy最新文献_第4页

Is organ preserving radical cystectomy in women oncologically safe and does it improve quality of life? 保留器官的根治性膀胱切除术在肿瘤学上是安全的吗？它能提高生活质量吗？

IF 2.8 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-09-01 Epub Date: 2025-07-03 DOI: 10.1080/14737140.2025.2525311

Alireza Aminsharifi, Sri Saran Manivasagam, Mohammad Reza Askarpour, Jay D Raman

{"title":"Is organ preserving radical cystectomy in women oncologically safe and does it improve quality of life?","authors":"Alireza Aminsharifi, Sri Saran Manivasagam, Mohammad Reza Askarpour, Jay D Raman","doi":"10.1080/14737140.2025.2525311","DOIUrl":"10.1080/14737140.2025.2525311","url":null,"abstract":"Introduction: Radical cystectomy in women with bladder cancer traditionally involves removal of reproductive organs, often leading to significant impairment in quality of life. Organ-preserving radical cystectomy (OPRC) has emerged as an alternative approach aimed at maintaining functional outcomes without compromising oncological safety.Methods: This systematic review evaluates current evidence on oncological, surgical, and functional outcomes of OPRC. A comprehensive literature search was conducted using the PubMed, Scopus, and Cochrane databases up to April 2025. Studies were assessed for methodological quality and risk of bias.Results: Fifteen studies (946 female patients) were included in the review. Data on patient selection criteria, operative parameters, recurrence, survival, continence, and sexual outcomes were discussed.Conclusion: OPRC is a safe and effective option for selected women with organ-confined disease. It offers superior functional outcomes and quality of life compared to standard radical cystectomy without compromising oncologic control. Several studies applied strict criteria, including premenopausal, sexually active women with organ-confined (≤T2) disease, away from bladder neck and no genital organ involvement on imaging. However, considerable heterogeneity existed in patient selection and definitions of functional outcomes. Further prospective trials and standardized criteria are warranted. Integrating these findings into practice guidelines could enhance patient-centered care in women undergoing cystectomy.Registration: PROSPERO (CRD420251045355).","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1075-1085"},"PeriodicalIF":2.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144474384","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Modeling large cell neuroendocrine carcinoma of the lung for molecular, therapeutic and microenvironmental inferences: current knowledge and future perspectives. 模拟肺大细胞神经内分泌癌的分子，治疗和微环境推断：目前的知识和未来的观点。

IF 2.8 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-09-01 Epub Date: 2025-06-26 DOI: 10.1080/14737140.2025.2523544

Giuseppe Pelosi, Maria Gemelli, Fabrizio Bianchi, Mauro Papotti, Eleonora Duregon, Riccardo Ricotta, Riccardo Papa, Sergio Harari, Angelica Sonzogni, Alice Laffi, Barbara Bassani, Antonino Bruno

{"title":"Modeling large cell neuroendocrine carcinoma of the lung for molecular, therapeutic and microenvironmental inferences: current knowledge and future perspectives.","authors":"Giuseppe Pelosi, Maria Gemelli, Fabrizio Bianchi, Mauro Papotti, Eleonora Duregon, Riccardo Ricotta, Riccardo Papa, Sergio Harari, Angelica Sonzogni, Alice Laffi, Barbara Bassani, Antonino Bruno","doi":"10.1080/14737140.2025.2523544","DOIUrl":"10.1080/14737140.2025.2523544","url":null,"abstract":"Introduction: Large cell neuroendocrine carcinoma (LCNEC) of the lung is a high-grade non-small cell carcinoma featuring neuroendocrine morphology and neuroendocrine markers. Despite being credited since decades as an independent tumor entity, it continues to represent a diagnostic and therapeutic challenge probably because makes up a heterogeneous melting pot of genetic and epigenetic alterations closely intertwined with host microenvironment.Areas covered: LCNEC of the lung was untangled according to three converging outlooks: (i) diagnostic criteria and molecular alterations as conveyors of pathogenetic diversification; (ii) microenvironmental changes, including immune system, as culprits behind tumor development; and (iii) available clinical trials, including immune-oncology studies as clinical decision-making drivers.Expert opinion: LCNEC of the lung unveils different developmental trajectories, which may account for troubles in diagnosis and clinical decision-making but, at the same time, offer a rationale for personalized targeted treatments or immunotherapy in patient subsets. Currently, the question is fascinating: are we actually ready for a radical route change in the understanding of LCNEC? The answer is still open, but future studies will need to frame LCNEC in its own overarching context among lung cancers according to a holistic vision, which does not limit us to its perception as being 'just one tumor.'","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1021-1044"},"PeriodicalIF":2.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144340054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Innovations in laparoscopic management of endometrial cancer. 子宫内膜癌腹腔镜治疗的创新。

IF 2.8 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-09-01 Epub Date: 2025-06-18 DOI: 10.1080/14737140.2025.2520965

Giorgio Bogani, Mario M Leitao, Pedro T Ramirez, Luigi De Vitis, Anna Giudici, Vincenzo Tarantino, Evelyn A Reynolds, Andrea Mariani

{"title":"Innovations in laparoscopic management of endometrial cancer.","authors":"Giorgio Bogani, Mario M Leitao, Pedro T Ramirez, Luigi De Vitis, Anna Giudici, Vincenzo Tarantino, Evelyn A Reynolds, Andrea Mariani","doi":"10.1080/14737140.2025.2520965","DOIUrl":"10.1080/14737140.2025.2520965","url":null,"abstract":"Introduction: Endometrial cancer is one of the most common gynecologic malignancies, with increasing incidence, in developed countries. Advances in minimally invasive surgery, particularly laparoscopic with or without the use of computer-assisted ('robotic') platforms, have transformed its management, improving surgical outcomes and patient recovery.Areas covered: This review explores recent innovations in laparoscopic management of endometrial cancer, including robotic-assisted laparoscopic surgery, sentinel lymph node mapping, and the integration of artificial intelligence in surgical navigation. A comprehensive literature search was conducted using PubMed and clinical trial databases to assess the impact of these advancements on surgical precision, oncologic outcomes, and patient recovery. Major studies comparing robotic-assisted laparoscopy, traditional laparoscopy, and open surgery are reviewed, along with new technologies that support real-time decision-making during surgery.Expert opinion: Minimally invasive approaches have become the standard of care for early-stage endometrial cancer, offering superior perioperative outcomes. While robotic-assisted surgery provides technical advantages, cost and accessibility remain challenges. Sentinel lymph node mapping reduces morbidity compared to full lymphadenectomy, and artificial intelligence holds promise in optimizing surgical precision. Future research should focus on refining these technologies, improving patient selection criteria, and ensuring equitable access to advanced surgical techniques.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1057-1064"},"PeriodicalIF":2.8,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144301437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Is the ketogenic diet still controversial in cancer treatment? 生酮饮食在癌症治疗中仍有争议吗？

IF 2.8 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-09-01 Epub Date: 2025-06-20 DOI: 10.1080/14737140.2025.2522936

Rainer Johannes Klement

引用次数: 0

Association of RAD51 expression with response to neoadjuvant treatment and prognosis in locally advanced gastric cancer. 局部晚期胃癌患者RAD51表达与新辅助治疗反应及预后的关系

IF 2.8 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-08-30 DOI: 10.1080/14737140.2025.2555468

Serhat Sekmek, Serhat Ozan, Fahriye Tugba Kos, Hayriye Tatli Dogan, Mehmet Akif Parlar, Didem Sener Dede

{"title":"Association of RAD51 expression with response to neoadjuvant treatment and prognosis in locally advanced gastric cancer.","authors":"Serhat Sekmek, Serhat Ozan, Fahriye Tugba Kos, Hayriye Tatli Dogan, Mehmet Akif Parlar, Didem Sener Dede","doi":"10.1080/14737140.2025.2555468","DOIUrl":"https://doi.org/10.1080/14737140.2025.2555468","url":null,"abstract":"Background: We aimed to investigate the effect of RAD51 expression on pathological response and survival in gastric cancer patients receiving fluorouracil plus leucovorin, cisplatin and docataxel (FLOT) as neoadjuvant chemotherapy (NACT).Research design and methods: RAD51 immunohistochemistry staining was performed in the endoscopy biopsies of the patients, and the pathological responses in the surgery of the patients after NACT were evaluated using the Ryan tumor regression score (RTRS).Results: 89 patients participated in this study. The factors affecting the pathological responses of the patients after NACT were examined, patients with high RAD51 nuclear expression percentage (NEP) responded better to NACT (p = 0.020). RAD51 nuclear expression density (NED) (p = 0.127), age (p = 0.999), sex (p = 0.098), clinical stage (p = 0.540), tumor pathology (p = 0.999) did not affect the pathological response after NACT. Age, gender, clinical stage, tumor pathology, RAD51 NEP or RAD51 NED did not affect DFS or OS. Patients with low RTRS had better DFS (p = 0.001) and OS (p = 0.009) results.Conclusions: As a result of our study, it was observed that patients with high RAD51 NEP had better pathological responses after NACT.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-7"},"PeriodicalIF":2.8,"publicationDate":"2025-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144948016","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advancing patient-centered care in myelodysplastic syndromes/neoplasms with oral therapies. 通过口服治疗推进骨髓增生异常综合征/肿瘤以患者为中心的护理

IF 2.8 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-08-27 DOI: 10.1080/14737140.2025.2550804

Pasquale Niscola, Fabio Efficace

引用次数: 0

Genetic investigation in patients with histological variants of bladder cancer: clinical implications. 膀胱癌组织学变异患者的遗传学研究：临床意义。

IF 2.8 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-08-25 DOI: 10.1080/14737140.2025.2548487

Nikoo Emtiazi, Ehsan Zolfi, Farhood Khaleghi Mehr

{"title":"Genetic investigation in patients with histological variants of bladder cancer: clinical implications.","authors":"Nikoo Emtiazi, Ehsan Zolfi, Farhood Khaleghi Mehr","doi":"10.1080/14737140.2025.2548487","DOIUrl":"10.1080/14737140.2025.2548487","url":null,"abstract":"Introduction: Understanding histological variants is crucial for accurate diagnosis and management of bladder cancer (BC). Most BCs are urothelial carcinomas (UC), which can evolve into aggressive histological variants (HVs) such as micropapillary, plasmacytoid, small-cell carcinoma, and sarcomatoid subtypes.Areas covered: This review will focus on the clinicopathologic characteristics of the most common non-urothelial and other rare variants (signet-ring cell variant, decoy cells, osteoclastic giant cell variant) BCs, to be distinguished from BC variant histology containing a UC component. In addition, we reviewed the effects of understanding HVs in developing therapeutic and diagnostic methods for BC. Our analysis combines evidence from searches in PubMed/NCBI, Google Scholar, ClinicalTrials.gov, and key conference proceedings from 2011 to 2025.Expert opinion: Recognizing and differentiating between various variant histology (VH) subtypes is crucial for tailoring treatment strategies and improving patient outcomes. Discovering and uniform reporting of variant histology in UC is essential. Clinical trials focusing specifically on patients with HVs are needed to evaluate the impact of new treatment modalities and optimize management strategies. More clinical studies with specific guidelines and goals, along with research, patient records, databases, and tissue banks, are needed to improve treatment plans and identify markers for patients with urinary tract cancer.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-23"},"PeriodicalIF":2.8,"publicationDate":"2025-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144859020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Innovation in next-generation sequencing in non-small cell lung cancer diagnostics. 新一代测序在非小细胞肺癌诊断中的创新。

IF 2.8 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-08-25 DOI: 10.1080/14737140.2025.2549538

Claudia Scimone, Lucia Palumbo, Roberto Borea, Claudia Sarracino, Ilaria Tomaiuolo, Domenica Di Giovanni, Sabrina Alfano, Mariantonia Nacchio, Gianluca Russo, Alessandro Russo, Francesco Pepe, Giancarlo Troncone, Umberto Malapelle

{"title":"Innovation in next-generation sequencing in non-small cell lung cancer diagnostics.","authors":"Claudia Scimone, Lucia Palumbo, Roberto Borea, Claudia Sarracino, Ilaria Tomaiuolo, Domenica Di Giovanni, Sabrina Alfano, Mariantonia Nacchio, Gianluca Russo, Alessandro Russo, Francesco Pepe, Giancarlo Troncone, Umberto Malapelle","doi":"10.1080/14737140.2025.2549538","DOIUrl":"10.1080/14737140.2025.2549538","url":null,"abstract":"Introduction: In the era of precision medicine, molecular biomarker testing is increasingly becoming the standard of care for Non-Small Cell Lung Cancer (NSCLC) patients. Tissue and liquid biopsy-based Next-Generation Sequencing (NGS) is now highly recommended.Areas covered: Different NGS platforms emerged as a cost-effective strategy to perform a massive and parallel sequencing performing higher technical sensitivity than old generation technologies in detecting low abundant alterations in challenging diagnostic samples. NGS systems can detect single nucleotide variants (SNV), small insertions, and deletions (indels), copy number alterations (CNAs) and structural variants (SVs) or gene fusions across selected druggable genes optimizing clinical administration of NSCLC patients. The diagnostic implementation of the most adequate NGS panel depending on several factors that could impact on the clinical utility of the testing assay.Expert opinion: Promising advanced technologies are emerging as potentially integrative tools in personalized medicine. In this context, multi-omic evaluation including genomic, transcriptomic, fragmentomic and epigenomic signatures are under investigation to significantly modify clinical algorithms of NSCLC patients. On this basis, sequencing strategies may play a pivotal role in the implementation of a new predictive model for cancer diagnosis and prognosis.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-19"},"PeriodicalIF":2.8,"publicationDate":"2025-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144872163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Desmoid tumor control with liposomal doxorubicin: a dual-center retrospective analysis. 阿霉素脂质体控制硬纤维瘤：双中心回顾性分析。

IF 2.8 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-08-21 DOI: 10.1080/14737140.2025.2545551

Victoria Wytiaz, Rodney Dixon Dorand, Sean Cohen, Vicki Leigh Keedy, Scott C Borinstein, Scott Schuetze, Rashmi Chugh, Elizabeth J Davis

{"title":"Desmoid tumor control with liposomal doxorubicin: a dual-center retrospective analysis.","authors":"Victoria Wytiaz, Rodney Dixon Dorand, Sean Cohen, Vicki Leigh Keedy, Scott C Borinstein, Scott Schuetze, Rashmi Chugh, Elizabeth J Davis","doi":"10.1080/14737140.2025.2545551","DOIUrl":"10.1080/14737140.2025.2545551","url":null,"abstract":"Background: Desmoid tumors are rare, locally aggressive tumors that are often life-affecting with a significant burden on afflicted patients. While systemic therapy for progressive disease is often preferred, there is a paucity of studies comparing disease control rates of agents based on tumor location or other disease-related factors.Methods: Dual-center retrospective analysis of disease control in patients with intra-abdominal (IA) and extra-abdominal (EA) desmoid tumors who received liposomal doxorubicin (LD). Disease control rate (DCR) was defined as stable disease (if evidence of progression prior to LD therapy) or partial response.Results: 54 patients were included, 38.9% (21/54) with IA desmoid tumors and 35.2% (19/54) with Familial Adenomatous Polyposis (FAP)-associated desmoid tumors. DCRs for patients with IA and EA desmoid tumors were 76.2% and 45.5%, respectively (odds ratio 3.80; p = 0.03). The DCR for patients with FAP-associated desmoid tumors was 73.7%, compared to 48.6% for those without FAP (odds ratio 2.96, p = 0.09). Mean times to next treatment were 80.5 weeks and 36.3 weeks for patients with and without FAP.Conclusion: LD is effective and well-tolerated with a high potential for tumor control and prolonged duration of time until next treatment, especially in patients with FAP and IA desmoid tumors.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1-7"},"PeriodicalIF":2.8,"publicationDate":"2025-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144872162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The cost-effectiveness of toripalimab combined with chemotherapy versus chemotherapy alone in the first-line treatment of extensive-stage small cell lung cancer in China: the perspective of the medical and health system based on the EXTENTORCH study. 托利哌单抗联合化疗与单独化疗一线治疗中国广泛期小细胞肺癌的成本-效果分析：基于EXTENTORCH研究的医疗卫生系统视角

IF 2.8 3区医学

Expert Review of Anticancer Therapy Pub Date : 2025-08-18 DOI: 10.1080/14737140.2025.2549007

Xueying Jin, Shengkai Zhao, Zekai Zhao, Jianguo Zhao

{"title":"The cost-effectiveness of toripalimab combined with chemotherapy versus chemotherapy alone in the first-line treatment of extensive-stage small cell lung cancer in China: the perspective of the medical and health system based on the EXTENTORCH study.","authors":"Xueying Jin, Shengkai Zhao, Zekai Zhao, Jianguo Zhao","doi":"10.1080/14737140.2025.2549007","DOIUrl":"https://doi.org/10.1080/14737140.2025.2549007","url":null,"abstract":"Objective: To evaluate the cost-effectiveness of toripalimab combined with chemotherapy for the first-line treatment of extensive-stage small cell lung cancer.Methods: A partitioned survival model was employed with data sourced from the EXTENTORCH clinical trial and related literature. The simulation period was set to 10 years, with a cycle of 3 weeks, and all cost and utility indicators were adjusted using a 5% annual discount rate. Using QALYs as the main evaluation indicator, ICERs were calculated to compare the economic differences between treatment with TC group and PC group. The reliability of the research results was verified through single-factor sensitivity analysis and probabilistic sensitivity analysis.Results: From the base analysis indicate that the ICER for the TC group relative to the PC group is $3,151 per QALY, which is significantly lower than the WTP set at three times the 2024 per capita GDP of China. Sensitivity analysis shows that the discount rate, incidence of hematotoxicity in TC group, number of treatment cycles and other parameters have the greatest impact on ICER.Conclusion: At the current willingness-to-pay threshold for Chinese patients, the combination of toripalimab and chemotherapy demonstrates superior cost-effectiveness compared to traditional chemotherapy.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":""},"PeriodicalIF":2.8,"publicationDate":"2025-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144872164","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0